Sunday, October 22, 2017
Home Authors Posts by Cell Tribune

Cell Tribune

38 POSTS 0 COMMENTS
CellTribune.com provides business and research news updates for the cell and gene therapy industry. CellTribune follows the companies and people who drive innovation in this exciting technology. The goal of CellTribune is to be recognized as the media leader and the go-to source for originally-reported, quality news coverage in this industry. We strive to become the link between budding companies, analysts and institutional investors. Submit your press release to Cell Tribune for immediate publication.

Stem cell biologist at Harvard retracts diabetes breakthrough manuscript published in...

A diabetes breakthrough manuscript published by Douglas A. Melton, PhD, Co-Director of Harvard Stem Cell Institute (Ref: Cell 153, 747–758; May 9, 2013) In this article,...

Pluristem and New York Blood Center to Collaborate in Evaluating PLX-R18...

Prior research has suggested that PLX-R18 helps cord blood cells to engraft more rapidly and effectively Grant of $900,000 from Israel-U.S. Binational Industrial...

PharmaCyte Biotech’s Cannabinoid Therapy May Offer Potential for Childhood Brain Cancers

LAGUNA HILLS, Calif., Dec. 27, 2016 - PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and...

Self-organized amniogenesis by human pluripotent stem cells in a biomimetic implantation-like...

Amniogenesis—the development of amnion—is a critical developmental milestone for early human embryogenesis and successful pregnancy1, 2. However, human amniogenesis is poorly understood due to...

Fred Hutch announces $1M in grants to commercialize cutting-edge cancer and...

Fred Hutchinson Cancer Research Center, which has spun-out companies such as Juno Therapeutics and Nohla Therapeutics in recent years, is continuing its aggressive push to...

Thermo Fisher Scientific Acquires MTI-GlobalStem

Thermo Fisher Scientific, the world leader in serving science, today announced it has signed a purchase agreement to acquire MTI-GlobalStem, a privately-held company that...

Helix BioPharma Corp. announces the signing of a non-binding letter of...

Helix BioPharma Corp., a clinical stage immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced that it has signed a...

STEMCELL Technologies Signs Exclusive License Agreement with Cincinnati Children’s for Stem...

VANCOUVER, BRITISH COLUMBIA, December 19th, 2016 – STEMCELL Technologies Inc. has signed an exclusive license agreement with Cincinnati Children’s Hospital Medical Center to commercialize...

MaxCyte, Washington University collaborate to develop next generation CAR-based cell therapies

MaxCyte, Inc. announced a strategic collaboration with Washington University in St. Louis, a leading institution in acute myeloid leukemia (AML) research. MaxCyte and the...

Vericel Corporation Announces Exercise of Underwriters’ Over-Allotment Option and Closing of...

CAMBRIDGE, Mass., Dec. 21, 2016 - Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious...